BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//hacksw/handcal//NONSGML v1.0//EN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20260610T214747Z
DESCRIPTION:Click for Latest Location Information: http://edw2023digital.da
 taversity.net/sessionPop.cfm?confid=155&proposalid=14212\nThe ISO standards
  for Identification of Medicinal Products (IDMP) provide an internationally
  accepted framework to uniquely identify and describe medicinal products. D
 riven by regulatory requirements, the role of IDMP is to align the pha
 rmaceutical industry with data standards that enable the unambiguous identi
 fication of products and the substances they contain. IMDP implem
 entation efforts at numerous large pharmaceutical companies have only parti
 ally achieved these goals, though. They are diverse, built in sil
 os, not fully standardized, and have already created inconsistencies of int
 erpretation, in part due to ambiguities and gaps in the standards they depe
 nd on. As a consequence, there is a very real risk that envisioned benefits
  from IDMP in drug safety, innovation, and other areas cannot be fully real
 ized. Instead of concentrating on pharmaceutical innovations in new and rep
 urposed medicines, the companies required to use these standards strug
 gle with data issues.\n\nWork is ongoing to specify an ISO IDMP Logical Mod
 el that details data requirements in a technology-independent manner. Reali
 zation of the full potential of IDMP requires, however, taking this one ste
 p further and ensuring that the data is (1) unambiguously specified, (2) fu
 lly self-describing, and (3) interoperable across the pharmaceutical compan
 ies and regulatory agencies that govern their work. To that end, a diverse 
 team of pharmaceutical companies, regulators, and technologists have come t
 ogether to augment the existing standard and logical model with a
 n IDMP Ontology that enables deep, semantic interoperability based on FAIR 
 principles. This will ultimately enable entirely new ways of collaboration 
 and enable early adopters to gain a competitive advantage in innovation, dr
 ug safety, and overall operational efficiency.\n\nIn this talk, Ms. Kendall
 , who is the lead ontologist for the project, will provide an overview of t
 he project, present the approach taken to demonstrate clear and compelling 
 results to project stakeholders in an initial 6-month phase, and discu
 ss lessons learned in comparison with other industry ontology efforts as we
 ll as progress since that initial release in September 2022.\n
DTSTART:20230329T120000
SUMMARY:Ontologies: A Leading Edge Case Study
DTEND:20230329T124959
LOCATION: See Description
END:VEVENT
END:VCALENDAR